INFLAMMATORY BOWEL DISEASE, SERIES #68Dietary Interventions in Patients with Inflammatory Bowel Disease
In this article we review the current evidence for dietary constituents as risk factors for the development of IBD and critically discuss the reports on the efficacies of dietary and enteral interventions.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #91Nasal Bridle: Married to Your Tube
New data has emerged suggesting that bridles may delay or decrease the need for percutaneous endoscopic gastrostomy (PEG) placement, and as a result, the 30-day mortality associated with it. This review describes the technique of bridle placement and the latest outcomes data.
A CASE REPORTCongenital Type 1 Choledochal Cyst in an Adult Male Presenting with Primary Invasive Cholangiocarcinoma
We present a rare case of a patient with Type 1 choledochal cyst presenting with invasive cholangiocarcinoma.
A case for you to solve
Early Detection and Prevention of Colorectal Cancer
Early Detection and Prevention of Colorectal Cancer edited by Dr. Karen E. Kim is a hardcover book meant to be a comprehensive resource yet useful reference for practicing physicians in adult medicine or gastroenterology, as well as trainees and allied health professionals.
IL-28B as a Pre-Treatment Predictor of SVR in Genotype I HCV
To confirm the polymorphisms clinical relevance of IL-28B as associated with a two-fold distance in sustained virologic response (VR) to PEG Interferon-Alfa and Ribavirin therapy, intention to treat analysis was carried out on-treatment virologic response SVR.
Lymphocytic Enteropathy and Celiac Disease
A prospective study to determine the clinical, pathologic, and serologic spectrum of celiac disease in a general population was carried out by random sample of an adult general population (N = 1000), analyzed by upper endoscopy, duodenal biopsy, and serologic analysis of tissue transglutaminase (tTg) levels, endomysialantibody (EMA), when tTg was positive.
Thioketal Nanoparticles: Researchers Develop Oral Delivery System to Treat Inflammatory Bowel Diseases
Researchers at the Georgia Institute of Technology and Emory University have developed a novel approach for delivering small bits of genetic material into the body to improve the treatment of inflammatory bowel diseases.
Merckís Investigational Medicine Boceprevir Achieved Significantly Higher SVR Rates In Treatment-Failure and Treatment-NaÔve Adult Patients with Chronic Hepatitis C Genotype 1 Compared to Control
Merck has reported that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment- failure; HCV RESPOND-2) and in adult patients who were new to treatment (treatment-naÔve; HCV SPRINT-2) for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.